

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 October 2023 (05.10.2023)



(10) International Publication Number
WO 2023/192977 A2

(51) International Patent Classification:
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/US2023/065196

(22) International Filing Date:
31 March 2023 (31.03.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/326,770 01 April 2022 (01.04.2022) US
63/326,813 02 April 2022 (02.04.2022) US

(71) Applicant: **ALNYLAM PHARMACEUTICALS, INC.**
[US/US]; 675 West Kendall Street, Henri A. Termeer
Square, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **HOANG DANG, Lan Thi**; 675 West Kendall
Street, Henri A. Termeer Square, Cambridge, Massachu-
setts 02142 (US). **SCHLEGEL, Mark K.**; 675 West
Kendall Street, Henri A. Termeer Square, Cambridge,
Massachusetts 02142 (US). **BARRY, Joseph**; 675 West
Kendall Street, Henri A. Termeer Square, Cambridge,
Massachusetts 02142 (US). **NGUYEN, Tuyen**; 675 West
Kendall Street, Henri A. Termeer Square, Cambridge,
Massachusetts 02142 (US). **CASTORENO, Adam**; 675
West Kendall Street, Henri A. Termeer Square, Cambridge,
Massachusetts 02142 (US). **SO, Kawai**; 675 West Kendall
Street, Henri A. Termeer Square, Cambridge, Massachu-
setts 02142 (US).

(74) Agent: **COWLES, Christopher R.**; Withers Bergman
LLP, 101 Federal Street, Suite 1900, Boston, MA 02110,
Boston, Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

— with declaration under Article 17(2)(a); without abstract;
title not checked by the International Searching Authority
— with sequence listing part of description (Rule 5.2(a))

WO 2023/192977 A2

(54) Title: SNCA-TARGETING SIRNA COMPOSITIONS FOR TREATING SNCA-ASSOCIATED DISEASE

(57) Abstract: